Our results define a previously unreported, gut microbiota-dependent regulatory axis wherein YCHZX alleviates NASH by enriching specific butyrate-producing bacteria, suppressing colonic IDO1, and reprogramming tryptophan metabolism toward ILA production. This evidence concerns the gene IDO1 and metabolic dysfunction-associated steatohepatitis.